Abstract
Ligand efficient fragments binding to PDK1 were identified by an NMR fragment-based screening approach. Computational modeling of the fragments bound to the active site led to the design and synthesis of a series of novel 6,7-disubstituted thienopyrimidin-4-one compounds, with low micromolar inhibitory activity against PDK1 in a biochemical enzyme assay.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
3-Phosphoinositide-Dependent Protein Kinases
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacology
-
Catalytic Domain
-
Computer Simulation
-
Drug Design
-
Humans
-
Kinetics
-
Ligands
-
Magnetic Resonance Spectroscopy
-
Mice
-
Models, Molecular
-
Protein Binding
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / metabolism
-
Pyrimidinones / chemical synthesis*
-
Pyrimidinones / pharmacology
Substances
-
Antineoplastic Agents
-
Ligands
-
Protein Kinase Inhibitors
-
Pyrimidinones
-
3-Phosphoinositide-Dependent Protein Kinases
-
PDPK1 protein, human
-
Pdpk1 protein, mouse
-
Protein Serine-Threonine Kinases